Farnesyl Protein transferase inhibitors with in vivo radiosensitizing properties

US6545020B1 · kind B1 · utility

Assignee

• Janssen Pharmaceutica NA · BE

Inventors

• Robert Franciscus Van Ginckel · Vorselaar, BE
• Wim Joanna Floren · Rijkevorsel, BE
• David William End · Ambler, US
• Walter Boudewijin Leopold Wouters · Kapellen, BE

Key dates

• Filing date: Jan 3, 2001
• Grant date: Apr 8, 2003
• Expiry date: Jan 3, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is concerned with the finding that farnesyl protein transferase inhibitors have radiosensitizing properties which makes them useful for preparing a pharmaceutical composition for administration before, during or after irradiation of a tumor for treating cancer in vivo.